ImmunoGen Valuation

Is 0A8K undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0A8K when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0A8K ($31.24) is trading above our estimate of fair value ($30.31)

Significantly Below Fair Value: 0A8K is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0A8K?

Key metric: As 0A8K is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0A8K. This is calculated by dividing 0A8K's market cap by their current revenue.
What is 0A8K's PS Ratio?
PS Ratio29.1x
SalesUS$287.61m
Market CapUS$8.36b

Price to Sales Ratio vs Peers

How does 0A8K's PS Ratio compare to its peers?

The above table shows the PS ratio for 0A8K vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.2x
GNS Genus
1.7x3.5%UK£1.1b
OXB Oxford Biomedica
4.6x21.0%UK£447.3m
BVXP Bioventix
14.4xn/aUK£195.7m
AVCT Avacta Group
8.1x0.4%UK£182.9m
0A8K ImmunoGen
29.1x26.0%US$8.4b

Price-To-Sales vs Peers: 0A8K is expensive based on its Price-To-Sales Ratio (29.1x) compared to the peer average (18x).


Price to Sales Ratio vs Industry

How does 0A8K's PS Ratio compare vs other companies in the GB Biotechs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.7x3.5%US$1.39b
OXB Oxford Biomedica
4.6x21.0%US$561.36m
TRX Tissue Regenix Group
1.6x15.1%US$50.96m
VRCI Verici Dx
2.4x78.8%US$10.27m
0A8K 29.1xIndustry Avg. 8.0xNo. of Companies8PS020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0A8K is expensive based on its Price-To-Sales Ratio (29.1x) compared to the UK Biotechs industry average (21.2x).


Price to Sales Ratio vs Fair Ratio

What is 0A8K's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0A8K PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio29.1x
Fair PS Ratio9.5x

Price-To-Sales vs Fair Ratio: 0A8K is expensive based on its Price-To-Sales Ratio (29.1x) compared to the estimated Fair Price-To-Sales Ratio (9.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0A8K forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$29.15
0%
13.7%US$31.26US$19.00n/a10
Nov ’25n/a
US$29.15
0%
13.7%US$31.26US$19.00n/a10
Oct ’25n/a
US$29.15
0%
13.7%US$31.26US$19.00n/a10
Sep ’25n/a
US$29.15
0%
13.7%US$31.26US$19.00n/a10
Aug ’25n/a
US$29.15
0%
13.7%US$31.26US$19.00n/a10
Jul ’25n/a
US$29.15
0%
13.7%US$31.26US$19.00n/a10
Jun ’25n/a
US$29.15
0%
13.7%US$31.26US$19.00n/a10
May ’25n/a
US$29.15
0%
13.7%US$31.26US$19.00n/a10
Apr ’25n/a
US$29.15
0%
13.7%US$31.26US$19.00n/a10
Mar ’25n/a
US$29.15
0%
13.7%US$31.26US$19.00n/a10
Feb ’25US$29.38
US$29.34
-0.1%
13.1%US$31.26US$19.00n/a11
Jan ’25US$29.68
US$29.34
-1.1%
13.1%US$31.26US$19.00n/a11
Dec ’24US$28.95
US$28.90
-0.2%
13.7%US$31.26US$19.00n/a12
Nov ’24US$14.80
US$23.08
+56.0%
17.8%US$27.00US$13.00n/a12
Oct ’24US$15.92
US$23.60
+48.3%
16.3%US$27.00US$13.00n/a10
Sep ’24US$16.02
US$22.30
+39.2%
26.2%US$27.00US$9.00n/a10
Aug ’24US$17.70
US$22.20
+25.4%
26.0%US$27.00US$9.00n/a10
Jul ’24US$18.97
US$17.60
-7.2%
28.4%US$24.00US$8.00n/a10
Jun ’24US$14.24
US$14.40
+1.1%
29.8%US$22.00US$8.00n/a10
May ’24US$5.39
US$12.10
+124.6%
45.5%US$22.00US$3.00n/a10
Apr ’24US$3.88
US$12.00
+209.3%
46.1%US$22.00US$3.00n/a10
Mar ’24US$3.95
US$12.00
+203.9%
46.1%US$22.00US$3.00n/a10
Feb ’24US$4.57
US$12.09
+164.7%
44.4%US$22.00US$4.00US$29.3810
Jan ’24US$4.80
US$11.99
+149.9%
45.3%US$22.00US$4.00US$29.6810
Dec ’23US$5.27
US$12.50
+137.2%
47.2%US$22.00US$4.00US$28.9510
Nov ’23US$5.50
US$10.89
+98.0%
44.5%US$20.00US$4.00US$14.809

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies